Ely Cosino
Research Subjects
Ely Cosino has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andrew G. Polson
Research and Early Development, Genentech Inc., South San Francisco, California.
21 shared publications - Christoph Spiess
Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
21 shared publications - Dorothee Nickles
Genentech Research and Early Development, Genentech Inc., South San Francisco, California
21 shared publications - Elicia Penuel
Genentech Inc
21 shared publications - Geoff Del Rosario
Genentech Research and Early Development, Genentech Inc., South San Francisco, California
21 shared publications - Greg A. Lazar
Department of Antibody Engineering, Genentech, Inc., South San Francisco, USA
21 shared publications
Latest Publications
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S1: Results of a differential gene expression analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S1: Results of a differential gene expression analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing impact the NK-cell transcriptome and their function.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing impact the NK-cell transcriptome and their function.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Gating strategy and time course of activation for circulating NK cells after Mosunetuzumab treatment.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Gating strategy and time course of activation for circulating NK cells after Mosunetuzumab treatment.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
NK cells exposed to TDB-treated cells have increased cytolytic function.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
NK cells exposed to TDB-treated cells have increased cytolytic function.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing alters surface protein expression on macrophages.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing alters surface protein expression on macrophages.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S2: Results of a gene set enrichment analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S2: Results of a gene set enrichment analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.